COPD Management Guidelines

Initial Treatment Selection

For symptomatic COPD patients with moderate to severe disease, the American College of Physicians recommends starting with a long-acting muscarinic antagonist (LAMA) such as tiotropium as first-line maintenance therapy 1
The European Respiratory Society suggests that short-acting bronchodilators (SABA or SAMA) used as needed are appropriate for patients with mild disease and minimal symptoms 2, 3
The Global Initiative for Chronic Obstructive Lung Disease recommends that either a short-acting β2-agonist (e.g., salbutamol) or anticholinergic (e.g., ipratropium) can be selected based on symptomatic response 2, 1

The American Thoracic Society recommends adding a LABA to create LAMA/LABA dual therapy if symptoms persist on LAMA alone 4
The Chest guidelines suggest that triple therapy (LAMA/LABA/ICS) reduces mortality compared to LAMA/LABA dual therapy alone 5
The European Respiratory Society recommends considering adding long-term macrolide therapy (e.g., azithromycin) for patients with history of exacerbations despite optimal maintenance inhalers 4

The American College of Chest Physicians recommends that metered-dose inhalers are the most cost-effective option, but proper technique is essential 1
The Thorax guidelines suggest that inhaler technique must be demonstrated before prescribing and re-checked periodically 2, 1
The Praxis Medical Insights guidelines recommend that beta-blocking agents (including eye drops) should be avoided in COPD patients as they can worsen bronchospasm 1

The Thorax guidelines recommend that smoking cessation is essential at all stages and prevents accelerated lung function decline 2, 3
The European Respiratory Society suggests that influenza vaccination is recommended, especially for moderate to severe disease 2, 3
The American Thoracic Society recommends that pulmonary rehabilitation improves exercise performance and reduces breathlessness in moderate to severe COPD 2, 3

Short-acting beta-2 agonists, such as salbutamol 200-400 µg or terbutaline 500-1000 µg, should be used as the first-line rescue medication for breakthrough symptoms in COPD patients, as they provide rapid bronchodilation 6
The Global Initiative for Chronic Obstructive Lung Disease guideline is not directly cited here but the Thorax journal suggests SABAs are typically preferred due to faster onset 6

Add ipratropium bromide 500 µg to SABA (combination rescue therapy) if the patient demonstrates poor response to SABA alone during acute exacerbations 6
Combined nebulized treatment (2.5-10 mg SABA with 250-500 µg ipratropium) should be considered in more severe exacerbations, particularly in patients requiring hospital admission 6

Use hand-held inhaler with salbutamol 200-400 µg or terbutaline 500-1000 µg as needed for mild exacerbations 6
Nebulized salbutamol 2.5-5 mg or terbutaline 5-10 mg, or ipratropium 500 µg given every 4-6 hours for 24-48 hours until clinical improvement for moderate to severe exacerbations 6
For patients with carbon dioxide retention and acidosis, drive the nebulizer with air rather than high-flow oxygen to avoid worsening hypercapnia 6

Once acute exacerbation improves, transition from nebulized bronchodilators to hand-held rescue inhalers 24-48 hours before hospital discharge 6
Observe patients for 24-48 hours after transitioning to ensure adequate symptom control with the hand-held device 6